133 related articles for article (PubMed ID: 30412404)
21. Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases.
Rivara S; Milazzo FM; Giannini G
Future Med Chem; 2016 Apr; 8(6):647-80. PubMed ID: 27057774
[TBL] [Abstract][Full Text] [Related]
22. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
Weissmann M; Bhattacharya U; Feld S; Hammond E; Ilan N; Vlodavsky I
Matrix Biol; 2019 Apr; 77():58-72. PubMed ID: 30096360
[TBL] [Abstract][Full Text] [Related]
23. Synthesis of a pseudo-disaccharide library and its application to the characterisation of the heparanase catalytic site.
Vinader V; Haji-Abdullahi MH; Patterson LH; Afarinkia K
PLoS One; 2013; 8(11):e82111. PubMed ID: 24260588
[TBL] [Abstract][Full Text] [Related]
24. Heparanase: a target for drug discovery in cancer and inflammation.
McKenzie EA
Br J Pharmacol; 2007 May; 151(1):1-14. PubMed ID: 17339837
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B; Yang Y
Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
[TBL] [Abstract][Full Text] [Related]
26. Involvement of disulfide bond formation in the activation of heparanase.
Simizu S; Suzuki T; Muroi M; Lai NS; Takagi S; Dohmae N; Osada H
Cancer Res; 2007 Aug; 67(16):7841-9. PubMed ID: 17699790
[TBL] [Abstract][Full Text] [Related]
27. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling.
Fux L; Feibish N; Cohen-Kaplan V; Gingis-Velitski S; Feld S; Geffen C; Vlodavsky I; Ilan N
Cancer Res; 2009 Mar; 69(5):1758-67. PubMed ID: 19244131
[TBL] [Abstract][Full Text] [Related]
28. Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.
Gozalbes R; Mosulén S; Ortí L; Rodríguez-Díaz J; Carbajo RJ; Melnyk P; Pineda-Lucena A
Bioorg Med Chem; 2013 Apr; 21(7):1944-51. PubMed ID: 23415087
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of anti-angiogenic activities of chitooligosaccharides may be through inhibiting heparanase activity.
Quan H; Zhu F; Han X; Xu Z; Zhao Y; Miao Z
Med Hypotheses; 2009 Aug; 73(2):205-6. PubMed ID: 19342181
[TBL] [Abstract][Full Text] [Related]
30. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase).
Gandhi NS; Freeman C; Parish CR; Mancera RL
Glycobiology; 2012 Jan; 22(1):35-55. PubMed ID: 21746763
[TBL] [Abstract][Full Text] [Related]
31. [Effects of cisplatin combined with heparanase inhibitor on proliferation and invasion of human nasopharyngeal carcinoma cells].
Li Y; Liu H; Huang YY; Pu LJ; Zhang XD; Jiang ZW; Jiang CC
Yao Xue Xue Bao; 2013 Apr; 48(4):609-14. PubMed ID: 23833953
[TBL] [Abstract][Full Text] [Related]
32. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent.
Ishida K; Hirai G; Murakami K; Teruya T; Simizu S; Sodeoka M; Osada H
Mol Cancer Ther; 2004 Sep; 3(9):1069-77. PubMed ID: 15367701
[TBL] [Abstract][Full Text] [Related]
33. Investigating Glycol-Split-Heparin-Derived Inhibitors of Heparanase: A Study of Synthetic Trisaccharides.
Ni M; Elli S; Naggi A; Guerrini M; Torri G; Petitou M
Molecules; 2016 Nov; 21(11):. PubMed ID: 27886097
[TBL] [Abstract][Full Text] [Related]
34. Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor.
Courtney SM; Hay PA; Buck RT; Colville CS; Phillips DJ; Scopes DI; Pollard FC; Page MJ; Bennett JM; Hircock ML; McKenzie EA; Bhaman M; Felix R; Stubberfield CR; Turner PR
Bioorg Med Chem Lett; 2005 May; 15(9):2295-9. PubMed ID: 15837312
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, Cytotoxic and Heparanase Inhibition Studies of 5-oxo-1-arylpyrrolidine-3- carboxamides of Hydrazides and 4-amino-5-aryl-4H-1,2,4-triazole-3-thiol.
Hari S; Swaroop TR; Preetham HD; Mohan CD; Muddegowda U; Basappa S; Vlodavsky I; Sethi G; Rangappa KS
Curr Org Synth; 2020; 17(3):243-250. PubMed ID: 32096746
[TBL] [Abstract][Full Text] [Related]
36. Dendrimer Heparan Sulfate Glycomimetics: Potent Heparanase Inhibitors for Anticancer Therapy.
Zubkova OV; Ahmed YA; Guimond SE; Noble SL; Miller JH; Alfred Smith RA; Nurcombe V; Tyler PC; Weissmann M; Vlodavsky I; Turnbull JE
ACS Chem Biol; 2018 Dec; 13(12):3236-3242. PubMed ID: 30480427
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides.
Miao HQ; Elkin M; Aingorn E; Ishai-Michaeli R; Stein CA; Vlodavsky I
Int J Cancer; 1999 Oct; 83(3):424-31. PubMed ID: 10495437
[TBL] [Abstract][Full Text] [Related]
38. Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase.
Mosulén S; Pineda-Lucena A; Carbajo RJ
Biomol NMR Assign; 2015 Apr; 9(1):15-9. PubMed ID: 24395156
[TBL] [Abstract][Full Text] [Related]
39. Production of heparin and λ-carrageenan anti-heparanase derivatives using a combination of physicochemical depolymerization and glycol splitting.
Poupard N; Groult H; Bodin J; Bridiau N; Bordenave-Juchereau S; Sannier F; Piot JM; Fruitier-Arnaudin I; Maugard T
Carbohydr Polym; 2017 Jun; 166():156-165. PubMed ID: 28385219
[TBL] [Abstract][Full Text] [Related]
40. Testing of potential glycan-based heparanase inhibitors in a fluorescence activity assay using either bacterial heparinase II or human heparanase.
Schoenfeld AK; Vierfuß S; Lühn S; Alban S
J Pharm Biomed Anal; 2014 Jul; 95():130-8. PubMed ID: 24667567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
